In this trial, the levels of transcripts of immune molecules, such as CD4 and CD8, were increased after treatment with adagrasib in patients with NSCLC harboring KRAS G12C and LKB1 coalterations. This evidence concerns the gene KRAS and non-small cell lung carcinoma.